Shivani Nyati, Head of Wealth at Swastika Investmart Ltd, expressed that the oversubscription and listing gain reflect investor confidence in Emcure's established brand, diversified product range, and global market presence. However, she noted that the pharmaceutical industry's regulatory challenges and potential supply chain disruptions remain areas of concern. While Emcure Pharma's listing performance has been strong and met pre-listing expectations, Nyati advised investors to be mindful of these risks. She recommended that investors maintain their positions, with a stop loss set at ₹1200, to safeguard against volatility.
Emcure Pharma lists at 31% premium; should you buy, sell or hold the stock? Business StandardEmcure Pharma IPO shares to make stock market debut today; strong listing gains likely Business TodayWhat Are Brokerages' Views On Emcure Pharma And Bansal Wire Listings? Business TodayEmcure Pharma IPO Listing: Shares debut at nearly 32% premium over IPO price CNBC TV 18Emcure Pharma IPO Listing Posts 31.45% Gains: Should You Hold, Sell or Buy? News 18Strong Listing: Emcure Pharma Makes Stellar Debut On Exchanges At 32% Premium From IPO Price Good ReturnsEmcure Pharma lists at 32% premium over issue price India TodayEmcure Pharma lists at 32% premium: Should you hold or sell? MSNEmcure Pharma closes 3% higher after making strong market debut; should you buy the stock now? MSN
